871 related articles for article (PubMed ID: 26735353)
21. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
22. KRAS Mutation Testing on Endoscopic Ultrasound-Guided Fine-Needle Aspiration Samples Improves the Diagnostic Accuracy of Pancreatic Cancer.
Yeung MCF; Shek TWH
Pancreas; 2022 Nov-Dec 01; 51(10):1365-1371. PubMed ID: 37099780
[TBL] [Abstract][Full Text] [Related]
23. K-ras mutation analysis of residual liquid-based cytology specimens from endoscopic ultrasound-guided fine needle aspiration improves cell block diagnosis of pancreatic ductal adenocarcinoma.
Sekita-Hatakeyama Y; Nishikawa T; Takeuchi M; Morita K; Takeda M; Hatakeyama K; Nakai T; Uchiyama T; Itami H; Fujii T; Mitoro A; Sho M; Ohbayashi C
PLoS One; 2018; 13(3):e0193692. PubMed ID: 29494669
[TBL] [Abstract][Full Text] [Related]
24. Digital PCR Improves Mutation Analysis in Pancreas Fine Needle Aspiration Biopsy Specimens.
Sho S; Court CM; Kim S; Braxton DR; Hou S; Muthusamy VR; Watson RR; Sedarat A; Tseng HR; Tomlinson JS
PLoS One; 2017; 12(1):e0170897. PubMed ID: 28125707
[TBL] [Abstract][Full Text] [Related]
25. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
Sun H; Zhang B; Li H
Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692
[TBL] [Abstract][Full Text] [Related]
26. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
27. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis.
Bournet B; Souque A; Senesse P; Assenat E; Barthet M; Lesavre N; Aubert A; O'Toole D; Hammel P; Levy P; Ruszniewski P; Bouisson M; Escourrou J; Cordelier P; Buscail L
Endoscopy; 2009 Jun; 41(6):552-7. PubMed ID: 19533561
[TBL] [Abstract][Full Text] [Related]
28. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.
Le Calvez-Kelm F; Foll M; Wozniak MB; Delhomme TM; Durand G; Chopard P; Pertesi M; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Vallee MP; Rinaldi S; Brennan P; McKay JD; Byrnes GB; Scelo G
Oncotarget; 2016 Nov; 7(48):78827-78840. PubMed ID: 27705932
[TBL] [Abstract][Full Text] [Related]
29. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
30. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.
Albury TM; Pandey V; Gitto SB; Dominguez L; Spinel LP; Talarchek J; Klein-Szanto AJ; Testa JR; Altomare DA
Neoplasia; 2015 Feb; 17(2):175-82. PubMed ID: 25748236
[TBL] [Abstract][Full Text] [Related]
31. Fluorescence in situ hybridization and K-ras analyses improve diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses.
Reicher S; Boyar FZ; Albitar M; Sulcova V; Agersborg S; Nga V; Zhou Y; Li G; Venegas R; French SW; Chung DS; Stabile BE; Eysselein VE; Anguiano A
Pancreas; 2011 Oct; 40(7):1057-62. PubMed ID: 21705950
[TBL] [Abstract][Full Text] [Related]
32. Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer.
Bournet B; Gayral M; Torrisani J; Selves J; Cordelier P; Buscail L
World J Gastroenterol; 2014 Aug; 20(31):10758-68. PubMed ID: 25152579
[TBL] [Abstract][Full Text] [Related]
33. [Will molecular diagnostics become established in pancreatic pathology?].
Sipos B; Sperveslage J
Pathologe; 2013 Nov; 34 Suppl 2():214-20. PubMed ID: 24196616
[TBL] [Abstract][Full Text] [Related]
34. Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS.
Duan YF; Li DF; Liu YH; Mei P; Qin YX; Li LF; Lin QX; Li ZJ
Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):204-9. PubMed ID: 23558076
[TBL] [Abstract][Full Text] [Related]
35. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma.
Hashimoto D; Arima K; Yokoyama N; Chikamoto A; Taki K; Inoue R; Kaida T; Higashi T; Nitta H; Ohmuraya M; Hirota M; Beppu T; Baba H
Pancreas; 2016 Sep; 45(8):1111-4. PubMed ID: 26967456
[TBL] [Abstract][Full Text] [Related]
37. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
[TBL] [Abstract][Full Text] [Related]
38. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
[TBL] [Abstract][Full Text] [Related]
39. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
40. Targeting mTOR dependency in pancreatic cancer.
Morran DC; Wu J; Jamieson NB; Mrowinska A; Kalna G; Karim SA; Au AY; Scarlett CJ; Chang DK; Pajak MZ; ; Oien KA; McKay CJ; Carter CR; Gillen G; Champion S; Pimlott SL; Anderson KI; Evans TR; Grimmond SM; Biankin AV; Sansom OJ; Morton JP
Gut; 2014 Sep; 63(9):1481-9. PubMed ID: 24717934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
